Jefferies Financial Group’s Celldex Therapeutics CLDX Stock Holding History

Jefferies Financial Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,000	Closed	-$1.29M	–	1888
2025 Q3	$1.29M	Sell	50,000 -7,000	-12%	-$162K	0.01%	787
2025 Q2	$1.16M	Buy	57,000 +2,000	+4%	+$38.9K	0.01%	685
2025 Q1	$998K	Sell	55,000 -2,335,398	-98%	-$52.2M	0.01%	812
2024 Q4	$60.4M	Buy	2,390,398 +2,369,398	+11,283%	+$64.4M	0.36%	52
2024 Q3	$714K	Buy	+21,000	New	+$800K	0.01%	880
2023 Q2	–	Sell	-3,000	Closed	-$108K	–	1722
2023 Q1	$108K	Sell	3,000 -20,000	-87%	-$863K	﹤0.01%	1424
2022 Q4	$1.03M	Buy	+23,000	New	+$821K	0.01%	868

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Jefferies Financial Group's CLDX Position: Q4 2025 in Review

Jefferies Financial Group sold out of Celldex Therapeutics (CLDX) in Q4 2025, closing a stake of 50,000 shares — an estimated $1.29M sold.

Jefferies Financial Group first reported a position in CLDX in Q4 2022 and held it in 7 quarters. The position peaked at $60.4M in Q4 2024. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

Jefferies Financial Group reported no remaining Celldex Therapeutics position as of Q4 2025 after selling out during the quarter.
Jefferies Financial Group sold 50,000 Celldex Therapeutics shares in Q4 2025, an estimated $1.29M.
Jefferies Financial Group first reported a position in Celldex Therapeutics in Q4 2022 and held it in 7 quarters.
Jefferies Financial Group's Celldex Therapeutics position peaked at $60.4M in Q4 2024.
185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on Jefferies Financial Group's 13F filing for Q4 2025, filed 9 Feb 2026.